RAPT Therapeutics Inc (RAPT)
7.85
-0.10
(-1.26%)
USD |
NASDAQ |
Apr 22, 16:00
7.865
+0.02
(+0.19%)
After-Hours: 20:00
RAPT Therapeutics Enterprise Value: 114.30M for April 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 22, 2024 | 114.30M |
| April 19, 2024 | 117.78M |
| April 18, 2024 | 117.08M |
| April 17, 2024 | 120.91M |
| April 16, 2024 | 124.04M |
| April 15, 2024 | 138.31M |
| April 12, 2024 | 160.93M |
| April 11, 2024 | 167.54M |
| April 10, 2024 | 155.01M |
| April 09, 2024 | 134.83M |
| April 08, 2024 | 130.65M |
| April 05, 2024 | 116.04M |
| April 04, 2024 | 119.87M |
| April 03, 2024 | 132.05M |
| April 02, 2024 | 126.83M |
| April 01, 2024 | 135.18M |
| March 28, 2024 | 153.62M |
| March 27, 2024 | 151.88M |
| March 26, 2024 | 133.44M |
| March 25, 2024 | 128.92M |
| March 22, 2024 | 131.00M |
| March 21, 2024 | 137.27M |
| March 20, 2024 | 143.18M |
| March 19, 2024 | 141.79M |
| March 18, 2024 | 131.00M |
| Date | Value |
|---|---|
| March 15, 2024 | 135.87M |
| March 14, 2024 | 133.79M |
| March 13, 2024 | 139.70M |
| March 12, 2024 | 118.48M |
| March 11, 2024 | 123.00M |
| March 08, 2024 | 157.10M |
| March 07, 2024 | 164.06M |
| March 06, 2024 | 159.19M |
| March 05, 2024 | 143.18M |
| March 04, 2024 | 142.83M |
| March 01, 2024 | 150.03M |
| February 29, 2024 | 135.93M |
| February 28, 2024 | 139.03M |
| February 27, 2024 | 150.38M |
| February 26, 2024 | 165.17M |
| February 23, 2024 | 141.09M |
| February 22, 2024 | 158.98M |
| February 21, 2024 | 191.31M |
| February 20, 2024 | 77.45M |
| February 16, 2024 | 734.46M |
| February 15, 2024 | 719.67M |
| February 14, 2024 | 720.01M |
| February 13, 2024 | 700.75M |
| February 12, 2024 | 750.97M |
| February 09, 2024 | 741.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
77.45M
Minimum
Feb 20 2024
999.05M
Maximum
Jan 06 2022
494.86M
Average
458.36M
Median
May 18 2023
Enterprise Value Benchmarks
| Emergent BioSolutions Inc | 861.26M |
| Avinger Inc | 15.46M |
| Tonix Pharmaceuticals Holding Corp | -1.190M |
| Skye Bioscience Inc | 418.45M |
| Axsome Therapeutics Inc | 3.160B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.88M |
| Total Expenses (Quarterly) | 33.22M |
| EPS Diluted (Quarterly) | -0.81 |
| Earnings Yield | -38.85% |
| Normalized Earnings Yield | -32.48 |